Zenas BioPharma (ZBIO) Equity Ratio (2023 - 2026)

Zenas BioPharma's Equity Ratio history runs 4 years deep, the most recent figure standing at 0.45 for Q1 2026.

• In Q1 2026, Equity Ratio fell 47.27% year-over-year to 0.45; the TTM figure through Mar 2026 stood at 0.45 (down 47.27% YoY), while the FY2025 annual figure was 0.63, down 25.27% from the prior year.
• Equity Ratio was 0.45 for Q1 2026 at Zenas BioPharma, down from 0.63 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.89 in Q3 2024 to a low of 3.31 in Q4 2023.
• Historically, Equity Ratio has averaged 0.22 across 4 years, with a median of 0.72 in 2025.
• The sharpest annual moves came in 2024 and 2026: Equity Ratio soared 125.51% in 2024, then slumped 47.27% in 2026.
• A 4-year view of Equity Ratio shows it stood at 3.31 in 2023, then jumped by 125.51% to 0.84 in 2024, then decreased by 25.27% to 0.63 in 2025, then dropped by 28.84% to 0.45 in 2026.
• The last three Equity Ratio figures came in at 0.45 (Q1 2026), 0.63 (Q4 2025), and 0.61 (Q3 2025), per Business Quant data.